MaxCyte, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
MaxCyte is a life sciences company providing cell-engineering instruments, consumables, leases, licenses and related services for cell therapy, drug discovery, biomanufacturing and research applications. The filing covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The financial statements are unaudited and prepared under U.S. GAAP.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $11.342 million | $8.576 million | +32% |
| Gross profit | $9.939 million | $7.576 million | +31% |
| Gross margin | 88% | 88% | Flat |
| Operating loss | $(12.275) million | $(13.178) million | Improved by $0.903 million |
| Net loss | $(9.526) million | $(10.882) million | Improved by $1.356 million |
| Net loss per share | $(0.09) | $(0.11) | Improved |
| Net cash used in operating activities | $(10.564) million | $(4.324) million | Use increased by $6.240 million |
Core revenue was $8.188 million, up 5%, comprising cell therapy revenue of $6.415 million, up 7%, and drug discovery revenue of $1.773 million, down 1%. Program-related revenue was $3.154 million, compared with $0.804 million, reflecting clinical and regulatory milestones under Strategic Platform License agreements.
Core revenue included disposables of $3.432 million, up 32%; instrument revenue of $1.928 million, down 12%; lease revenue of $2.604 million, down 7%; and other revenue of $0.224 million, up 29%.
Operating expenses were $22.214 million, up 7%. Research and development increased 10% to $6.678 million, sales and marketing increased 17% to $7.365 million, general and administrative expense decreased 5% to $7.103 million, and depreciation and amortization increased 17% to $1.068 million. Interest income increased 20% to $2.749 million, partly offsetting the operating loss.
Cash, liquidity and capital structure
- Cash and cash equivalents were $22.249 million at March 31, 2024, compared with $46.506 million at December 31, 2023.
- Short-term investments were $135.264 million and non-current investments were $45.031 million, producing cash and investments totaling approximately $202.5 million.
- Total liabilities were $31.571 million, including $18.640 million of operating lease liabilities. The company reported no debt obligations.
- Stockholders’ equity was $226.359 million, and accumulated deficit was $185.324 million.
- Investing cash outflows were $14.396 million, primarily reflecting $48.042 million of investment purchases, partially offset by $34.450 million of investment maturities and $0.804 million of capital expenditures.
- Management believes existing cash, investments and internally generated cash flows will fund operating expenses and capital expenditures for at least the next 12 months from issuance of the financial statements.
Material changes, outlook and risks
- Revenue growth was driven mainly by a $2.350 million increase in program-related revenue. Management cautions that milestone revenue is dependent on a small number of triggering events and may remain volatile.
- During the quarter, MaxCyte signed Strategic Platform License agreements with Lion TCR, Imugene and Wugen. The company announced an additional agreement with Be Biopharma on April 2, 2024.
- Management expects continued investment in research and development, sales and marketing, manufacturing capacity and product offerings. Research and development and general and administrative expenses are expected to increase in absolute dollars, while sales and marketing spending may rise before related revenue benefits materialize.
- The company expects long-term revenue growth from customer program advancement, increased disposable and instrument sales, expanded cell therapy adoption and additional license partnerships, but does not provide quantified full-year guidance in the filing.
- Key risks include dependence on customer and partner funding and program progress, variability in milestone revenue, competition in non-viral delivery technologies, manufacturing and supplier concentration, regulatory and intellectual-property risks, foreign exchange exposure, and the possibility that additional financing may be required.
- Two customers represented 23% and 18% of Q1 revenue. Two customers represented 23% of accounts receivable at quarter-end, and one supplier represented 29% of accounts payable.
- The company had no material legal proceedings and reported no material changes to previously disclosed risk factors. Disclosure controls were considered effective as of March 31, 2024.
Important facts for investors to verify
- Whether program-related milestone revenue remains elevated or normalizes in subsequent quarters.
- Growth in recurring core revenue, particularly disposables, versus instrument and lease revenue.
- Operating cash burn and the sustainability of the approximately $202.5 million cash-and-investment balance.
- Progress, timing and commercial economics of the 27 Strategic Platform License partnerships and newly signed agreements.
- Customer concentration, partner access to capital, supplier concentration and competitive pricing pressure.
- Potential dilution or financing needs if losses and operating cash outflows persist.
- Execution of the headquarters lease, which has approximately $27.7 million of remaining undiscounted payments through August 2035.